Abstract Aim The international FOxTROT trial, recently published in the Journal of Clinical
Oncology is the first randomized controlled trial testing neoadjuvant chemotherapy (NAC) …

Aim FOxTROT1 established a new standard of care for managing locally advanced colon
cancer (CC) with neoadjuvant chemotherapy (NAC). Six weeks of neoadjuvant oxaliplatin …

Background NAC has an established role in many solid tumours but its utility has not
previously been formally evaluated in colon cancer. Methods Pts with CT-staged T3-4 N0-2 …

Neoadjuvant systemic therapy has many potential advantages over up-front surgery,
including tumor downstaging, early treatment of micrometastatic disease, and providing an …

3504 Background: NAC is well established in many solid tumours but has not undergone
large-scale evaluation in colon cancer. Methods: Pts had operable, non-obstructed colon …

PURPOSE The role of neoadjuvant chemotherapy (NAC) in colon cancer remains unclear.
This trial investigated whether 3 months of modified infusional fluorouracil, leucovorin, and …

Background The role of perioperative or neoadjuvant chemotherapy for locally advanced
colon cancer is unclear. Emerging evidence such as the FOXTROT trial is challenging the …

Background There is increasing evidence to support the use of neoadjuvant chemotherapy
(NAC) in locally advanced colon cancer (LACC). However, its safety, efficacy and side effect …

LBA3503 Background: Locally advanced colon cancer presents a therapeutic challenge
regarding improving survival and minimizing side effects by optimizing the timing of surgical …

Background Preoperative or neoadjuvant chemotherapy (NAC) has emerged as a novel
alternative to treat locally advanced colon cancer (LACC), as in other gastrointestinal …